				LEO Pharma A/S Hur	garian Commercial Representa	tive Office				
									Disclosure period: 2018, Public	ation Date:27/06
Full name	HCPs: City of Principal Practice HCOs: city where registered	Country of Principal Practice	Principal Practice Address	Unique country identifier OPTIONAL		Contribution in the cost of events (Art. 3.01.1.b & 3.01.2.a)			Fee for service and consultancy (Art. 3.01.1.c & 3.01.2.c)	
(Art. 1.01)	(Art. 3)	(Schedule 1)	(Art. 3)	(Art. 3)	Donations and Grants to HCOs (Art. 3.01.1.a)	Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accommodation	Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation relevant to the contract	TOTAL OPT
		INDIVIDUAL NAMED		ers of value during a year for an individua	HCP will be summed up (detailed description	of each transfer must be available to the indi	vidual Recipient or p			
David Winkler	Budapest	Hungary	Hegedűs Gyula utca 43., 1136		N/A	N/A		156 205,88 Ft		156 205,
Emese Schmidt	Budapest	Hungary	Hermina út 7., 1146		N/A	N/A	44 000,00 Ft			44 000,0
Miklós Sárdy	Budapest	Hungary	Mária utca 41., 1085		N/A	N/A			100 000,00 Ft	100 000,
					OVE - in case information may not be disclosed	d for legal reasons				
Aggregate amount attributable to transfers of value to such Recipients					N/A	N/A	44 000,00 Ft		620 000,00 Ft	664 000,
Number of Recipients in aggregate disclosure					N/A	N/A	1		2	3
% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed					N/A	N/A	50,00 %		66,67 %	N/A
						ach transfer must be available to the individu	al Recipient or publi	authorities where required)		
Nékám Foundation	Budapest	Hungary	Mária u. 41, 1085 Budapest, Hungary, Reg. no. 9460		100 000,00 Ft					100 000,
Szodoray Alapítvány	Debrecen	Hungary	Nagyerdei krt. 98., 4032		150 000,00 Ft					150 000,
					OVE - in case information may not be disclosed	d for legal reasons				
Aggregate amount attributable to transfers of value to such Recipients										
Number of Recipients in aggregate disclosure										
% of the number of I	Recipients included in the aggregate disclosure in	the total number of Recipients	disclosed							N/A
					AGGREGATE DISCLOSURE					
_										
			Trai	nsfers of Value re Research & Develop	ment as defined - Article 3.03 and Schedu	ile 1				